Leveraged buyouts, growth capital, angel investments, and seed funding—these private transactions take place, largely out of the public’s eye, not only in Connecticut or Silicon Valley, but also in Beijing, Shenzhen, and Shanghai.
In 2016, China’s private equity (PE) and venture capital (VC) firms raised over $70 billion, more than 20% of total such funding globally. At the same time, these firms also deployed capital to the tune of $223 billion, accounting for more than 70% of global PE/VC investments.
As late comers, these Chinese firms have rapidly grown into formidable financiers. Most Chinese PE firms are particularly interested in products and services that can be commercialized and scaled up quickly in China. They tend to invest in areas that align with China’s shift to a more consumer-driven economy. Meanwhile, Chinese VCs have been active players globally, particularly in Silicon Valley. They have focused on areas such as artificial intelligence, Internet of Things, and electric vehicles.
China Everbright Investment and Asset Management was established in 2004 as a subsidiary of China Everbright. The asset manager has a private equity arm that focuses on energy, entertainment, environment, and healthcare sectors.
In October 2014, China Everbright Investment and Asset Management acquired Burke E. Porter Machinery Co. for $90 million. Burke E. Porter Machinery, based in Grand Rapids, MI, develops advanced electrical, mechanical, and software solutions for testing and production systems.
In May 2015, China Everbright Investment and Asset Management, along with Shanghai Fosun Pharmaceutical Group, Hopu Investments, and WuXi PharmaTech, acquired Ambrx. Located in La Jolla, CA, Ambrx develops innovative protein therapeutics for drug substances.